Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EU-Orphan Drug

3

FDA ORPHAN DRUG

3

FDA UNII

3

NCI_THESAURUS

3

CAS

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "EU ORPHAN DRUG|Positive|Treatment of acute radiation syndrome" in comments (approximate match)

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ENTOLIMOD

R1UQ6D1ECM

Subunit 1 (329) Similarity Search

Export Data
Sequence Search

Subunit 1 (329) Similarity Search

Status:

Investigational

Class:

PROTEIN

INTERLEUKIN-12 HUMAN RECOMBINANT

02FXP10O2U

Subunit 1 (306) Similarity Search Subunit 2 (197) Similarity Search

Export Data
Sequence Search

Subunit 1 (306) Similarity Search Subunit 2 (197) Similarity Search

Status:

Investigational

Class:

PROTEIN

RUSALATIDE ACETATE

9J556O9JPD

Subunit 1 (23) Similarity Search

Export Data
Sequence Search

Subunit 1 (23) Similarity Search

Status:

Investigational

Class:

PROTEIN

Rusalatide acetate (also known as chrysalin or TP 508) is a 23-amino acid peptide derived from human prothrombin; it represents part of the receptor-binding domain of the human thrombin molecule. Rusalatide acetate binds to high-affinity thrombin rec...

eptors and mimics cellular effects of thrombin at sites of tissue injury. Rusalatide acetate demonstrated safety and potential efficacy in phase I/II clinical trials for the treatment of diabetic foot ulcers. It interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. In addition, this drug participated in phase II clinical trial to determine the effectiveness of four doses for treating broken wrists in adults. However, this study was terminated because the drug did not demonstrate benefit compared to placebo. Rusalatide acetate was also studied as a cardiovascular drug. However, in January 2012, Capstone discontinued the development of rusalatide, for financial reasons. Recent studies show that a single injection of TP508 (rusalatide acetate) administered 24 h after irradiation significantly increases survival and delays mortality in murine models of acute radiation mortality. Thus, this drug is being developed as a potential nuclear countermeasure.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1